uniQure N. V. , a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.
Uniqure Nv stock last closed at $59.99, down 4.52% from the previous day, and has increased 827.2% in one year. It has overperformed other stocks in the Biotechnology industry by 8.54 percentage points. Uniqure Nv stock is currently +1,021.31% from its 52-week low of $5.35, and -7.91% from its 52-week high of $65.14.
As of Oct 16, 2025, there are 54.87M shares of QURE outstanding. The market cap of QURE is $3.29B. In the past 24 hours, 2.23M QURE shares were traded.
You will need an online brokerage account in order to access the NASDAQ market and buy QURE shares.
Based on our research, eToro is the best online stock brokerage. eToro gives you:
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've chosen the right brokerage, you need to fill out some personal information so you are able to invest in QURE stock today.
Now that you have filled out your info on the best stock market app, your next step is to transfer the money for your investment:
Watch this video walkthrough to see the process of transferring money into your new investment account.
After you have decided on the best place to buy Uniqure Nv stock, it's critical to analyze their stock before you invest, so you can wrap your head around the risk as well as the upside.
WallStreetZen was created to help average investors perform more accurate fundamental analysis in less time.
You can see all of the due diligence checks on QURE's stock page.
You can use many financial metrics, analyses, models, and charts to gauge QURE's fair value.
You can access additional valuation analysis on QURE's stock here.
Out of 10 Equities analysts who give recommendations on QURE, the consensus analyst rating on QURE is a Strong Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Kristen Kluska, a top 2% analyst from Cantor Fitzgerald maintains QURE with a strong buy rating and raises their QURE price target from $47.00 to $80.00, on Sep 25, 2025.
Cantor Fitzgerald's Kristen Kluska raised their price target on Uniqure Nv (NASDAQ: QURE) by 70.2% from $47 to $80 on 2025/09/25. The analyst maintained their Strong Buy rating on the stock.
On 2025/09/24, uniQure NV announced positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington’s disease.
Although some patients may want to wait for AMT-130 approval before taking action, the patient advocacy community is very enthusiastic about the drug, Kluska told readers.
The analyst said they are bullish that the past three years could back approval and adoption.
Kluska said the success likelihood of AMT-130 in the U.S. and in Europe has increased from 45% to 75% and from 15% to 45%, respectively.
Daniil Gataulin, a top 1% analyst from Chardan Capital maintains QURE with a strong buy rating and raises their QURE price target from $35.00 to $76.00, on Sep 25, 2025.
Paul Matteis, a bottom 17% analyst from Stifel Nicolaus maintains QURE with a strong buy rating and raises their QURE price target from $30.00 to $65.00, on Sep 24, 2025.
Joseph Schwartz, a top 26% analyst from Leerink Partners maintains QURE with a buy rating and raises their QURE price target from $48.00 to $68.00, on Sep 24, 2025.
Patrick Trucchio, a top 1% analyst from HC Wainwright & Co. reiterates QURE with a buy rating and maintains their QURE price target from $70.00 to $70.00, on May 29, 2025.
You can dig deeper into what analysts are saying on the Uniqure Nv stock forecast page.
Last year, QURE revenue was $14.34M. Over the past five year, QURE's revenue has increased by 21.98% per year. This was slower than the Biotechnology industry average of 68.13%.
You can research QURE's earnings and revenue performance here.
Over the past year, executives and large shareholders at QURE have sold more shares than they have bought.
Christian Klemt, Chief Financial Officer of QURE, was the latest QURE insider to buy. They bought $80,550.00 worth of QURE stock on Sep 26, 2025.
Research more about who owns QURE shares here.
No, Uniqure Nv doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
You have two main options:
Press the Open Trade button and your broker will place the order.
If you need more assistance investing in stocks on eToro, click the helpful video below:
Now that you own some QURE stock, you'll want to keep up with your stock purchase.
Create a watchlist to get notified of important updates regarding your QURE stock.
To reiterate, here are the 6 steps to buy Uniqure Nv stock:
If you require a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you want to get the latest scoop on your investment in Uniqure Nv, create a watchlist today.